A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as ...

Is the Galleri multi-cancer blood test worth it? A doctor's analyses of real-world performance data. Learn why no major ...

In the U.S., one in eight women will get breast cancer in their lifetime, and about half of them will have mastectomies. Many ...

RACINE — A disability services company will lay off 56 employees beginning in March, according to a notice filed with the Wisconsin Department of Workforce Development.

Designation strengthens BIZENGRI® development program in rare cholangiocarcinomaLEXINGTON, Mass., Feb. 5, 2026 /PRNewswire/ -- Partner Therapeutics, Inc.

In a significant move towards enhancing cancer detection and treatment, telehealth company Hims & Hers has announced the addition of Grail's Galleri multi-cancer blood test to its extensive digital ...

Ochsner's national study with The GRAIL Galleri® test is finding at least one hidden cancer a week in unsuspecting people. “I fully believe that in five, maybe 10 years, it will be routine to go to ...

Telehealth company Hims & Hers has added Grail’s blood cancer test Galleri to its offerings as the medtech has now sent off ...

Comprehensive biomarker testing is crucial for NSCLC treatment, yet disparities exist between academic and community settings ...

Cellares will establish a standardized platform manufacturing process on the Cell Shuttle and platform release assays on the Cell Q.

The key alterations sought are FGFR3 activating mutations or fusions/rearrangements (“susceptible” alterations), for potential use of the FGFR inhibitor erdafitinib (Balversa), and HER2 IHC expression ...

Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...